Testing MB-001 for moderate to severe ulcerative colitis
Part of Digestive system clinical trials.
This study tests an investigational drug called MB-001 for people with moderate to severe ulcerative colitis who have already tried standard treatments without success. It aims to see if the drug is safe and helps control inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderately to severely active ulcerative colitis, confirmed by a scope test (colonoscopy or flexible sigmoidoscopy).
- You have tried at least one standard UC treatment (like 5-ASA drugs, steroids, or a biologic) that didn't work well enough, stopped working, or caused side effects.
- You have not tried more than one advanced therapy (like vedolizumab, ustekinumab, or similar) without success.
- You are not currently in a very severe flare that needs hospital care, and you have not had major colon surgery or a stoma.
- You are not pregnant or breastfeeding, and agree to use contraception during the study and for 28 days after the last dose.
- You do not have active infections (like tuberculosis, hepatitis B or C, or C. diff) that are not being treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental tablet for people with moderate to severe ulcerative colitis that hasn't improved with standard treatments. It aims to see if the tablet can reduce symptoms and inflammation.
This trial tests an investigational drug called LIV001 in people with mild-to-moderate ulcerative colitis. It aims to see if the medicine can help calm inflammation in the colon and improve symptoms.
This study tests whether a new drug called Hemay005 can help people with moderate to severe ulcerative colitis (a chronic bowel condition causing inflammation and symptoms like diarrhea and abdominal pain) who haven't responded well to or can't tolerate standard treatments. The goal is to reduce inflammation and improve symptoms.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
This trial tests a specially designed supplement that aims to restore healthy gut bacteria in people with mild-to-moderate ulcerative colitis. The goal is to reduce inflammation and improve symptoms like rectal bleeding and bowel urgency.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.